From June 2023 to September 2025, only 16% to 38% of non-hospitalized US COVID-19 patients aged 65 years and older were given an antiviral prescription, while those aged 75 to 84 and older were more likely to receive such a prescription than younger patients, according to a report from Centers for Disease Control and Prevention (CDC) researchers.
For the study, published in Morbidity and Mortality Weekly Report, the team used electronic health records to evaluate factors tied to receipt of an antiviral prescription among non-hospitalized COVID-19 aged 65 years and older.
“Adults aged ≥65 years have the highest rates of COVID-19–related hospitalization,” the authors wrote. “Despite the proven benefit of COVID-19 antivirals in preventing severe outcomes, data suggest that their use is low among older adults.”
Prescription rates vary by age, race, season, vaccination status
The odds of receiving an antiviral prescription were greatest among those aged 75 to 84 years and 85 and older (adjusted odds ratio [aOR], 1.09 and 1.11, respectively), those of Asian (aOR, 1.42) or Hispanic (aOR, 1.24) race, and recipients of at least one COVID-19 vaccine dose (aOR, 1.73).
Encouraging annual COVID-19 vaccination and increased prescribing of antivirals among adults aged ≥65 years with COVID-19 could reduce the risk for severe illness and hospitalization in this population.
The proportion of COVID-19 outpatients aged 65 and older given an antiviral prescription was lower in spring 2024 (21%), fall and winter 2024-25 (23%), spring 2025 (16%), and summer 2025 (19%) than during other seasons (range, 37% to 38%). The odds of antiviral prescription were highest in summer 2024 (aOR, 1.05).
Among prescription recipients, 99% received it within 7 days of COVID-19 diagnosis, and 80% were prescribed nirmatrelvir-ritonavir (Paxlovid). Patients with at least one underlying condition and rural residents had lower odds of receiving an antiviral prescription. The chances of prescribing were lower when COVID-19 incidence was lower.
“Antivirals might be underprescribed among adults aged ≥65 years, and prescribing rates vary temporally,” the researchers concluded. “Encouraging annual COVID-19 vaccination and increased prescribing of antivirals among adults aged ≥65 years with COVID-19 could reduce the risk for severe illness and hospitalization in this population.”